Clinical Cancer Research The Science of Cancer Health Disparities
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Li, W. W.
Right arrow Articles by Bertino, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, W. W.
Right arrow Articles by Bertino, J. R.
Clinical Cancer Research Vol. 7, 2908-2911, September 2001
© 2001 American Association for Cancer Research

Regular Articles

Sensitivity of Soft Tissue Sarcoma Cell Lines to Chemotherapeutic Agents

Identification of Ecteinascidin-743 as a Potent Cytotoxic Agent1

Wei Wei Li, Naoto Takahashi, Suresh Jhanwar, Carlos Cordon-Cardo, Yaroslav Elisseyeff, Jose Jimeno, Glynn Faircloth and Joseph R. Bertino2

Laboratories of Molecular Pharmacology [W. W. L., N. T., Y. E., J. R. B.], Human Genetics [S. J.], and Molecular Pathology [C. C-C.], Memorial Sloan-Kettering Cancer Center, New York, New York 10021, and Pharma Mar, s.a., Madrid, Spain [J. J., G. F.]

The cytotoxic effects of ecteinascidin-743(ET-743), a novel marine natural product, were evaluated and compared with that of clinically used anticancer agents methotrexate, doxorubicin, etoposide, and paclitaxel in eight human soft tissue sarcoma (STS) cell lines. HT-1080, a fibrosarcoma cell line, and HS-42, a malignant mesodermal cell line, were the most sensitive of the cell lines to methotrexate, doxorubicin, etoposide, and paclitaxel. Other cell lines (IC50s) varied considerably and were more resistant to these agents. ET-743 was more potent than any of these agents, with IC50s in the pM range in all of the cell lines. Cytotoxicity of ET-743 was dose- and time-related (4–72 h exposure). Cytotoxic concentrations of ET-743 produced a S/G2 block in all of the cell lines tested. Three colon adenocarcinoma cell lines, HCT-8, HT-29, and HCT-116, and one breast cancer cell line, MCF-7, were 1–2 logs less sensitive to ET-743 than the STS cell lines. Cell lines were also characterized as to expression of oncogenes and tumor suppressor genes to attempt to correlate sensitivity of these cell lines to ET-743 and other chemotherapeutic agents. All of the cell lines except M8805, a malignant fibrous histiocytoma cell line, had mutations in p53 and/or overexpressed the MDM2 protein. Only HS-18, a liposarcoma cell line, lacked expression of the retinoblastoma protein. None of the cell lines had detectable expression of P-glycoprotein as measured by immunohistochemistry.

ET-743 is an extremely potent cytotoxic agent against human STS cell lines and is being evaluated as an antitumor agent in this disease.




This article has been cited by other articles:


Home page
 Ann OncolHome page
M. von Mehren, R. J. Schilder, J. D. Cheng, E. Temmer, T. M. Cardoso, F. G. Renshaw, E. Bayever, P. Zannikos, Z. Yuan, and R. B. Cohen
A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies
Ann. Onc., October 1, 2008; 19(10): 1802 - 1809.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. Fayette, I. R. Coquard, L. Alberti, D. Ranchere, H. Boyle, and J.-Y. Blay
ET-743: A Novel Agent with Activity in Soft Tissue Sarcomas
Oncologist, November 1, 2005; 10(10): 827 - 832.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Verweij
Ecteinascidin-743 (ET-743): Early Test or Effective Treatment in Soft Tissue Sarcomas?
J. Clin. Oncol., August 20, 2005; 23(24): 5420 - 5423.
[Full Text] [PDF]

Home page
 JCOHome page
R. Garcia-Carbonero, J.G. Supko, R.G. Maki, J. Manola, D.P. Ryan, D. Harmon, T.A. Puchalski, G. Goss, M.V. Seiden, A. Waxman, et al.
Ecteinascidin-743 (ET-743) for Chemotherapy-Naive Patients With Advanced Soft Tissue Sarcomas: Multicenter Phase II and Pharmacokinetic Study
J. Clin. Oncol., August 20, 2005; 23(24): 5484 - 5492.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
N. Martinez, M. Sanchez-Beato, A. Carnero, V. Moneo, J. C. Tercero, I. Fernandez, M. Navarrete, J. Jimeno, and M. A. Piris
Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients
Mol. Cancer Ther., May 1, 2005; 4(5): 814 - 823.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. Allavena, M. Signorelli, M. Chieppa, E. Erba, G. Bianchi, F. Marchesi, C. O. Olimpio, C. Bonardi, A. Garbi, A. Lissoni, et al.
Anti-inflammatory Properties of the Novel Antitumor Agent Yondelis (Trabectedin): Inhibition of Macrophage Differentiation and Cytokine Production
Cancer Res., April 1, 2005; 65(7): 2964 - 2971.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. M. Spees, T. P.F. Gade, G. Yang, W. P. Tong, W. G. Bornmann, R. Gorlick, and J. A. Koutcher
An 19F Magnetic Resonance-Based In Vivo Assay of Solid Tumor Methotrexate Resistance: Proof of Principle
Clin. Cancer Res., February 15, 2005; 11(4): 1454 - 1461.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Lau, J. G. Supko, S. Blaney, L. Hershon, N. Seibel, M. Krailo, W. Qu, D. Malkin, J. Jimeno, M. Bernstein, et al.
A Phase I and Pharmacokinetic Study of Ecteinascidin-743 (Yondelis) in Children with Refractory Solid Tumors. A Children's Oncology Group Study
Clin. Cancer Res., January 15, 2005; 11(2): 672 - 677.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. G. Magro, A. J. Russo, W.-W. Li, D. Banerjee, and J. R. Bertino
p14ARF Expression Increases Dihydrofolate Reductase Degradation and Paradoxically Results in Resistance to Folate Antagonists in Cells with Nonfunctional p53
Cancer Res., June 15, 2004; 64(12): 4338 - 4345.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Yovine, M. Riofrio, J.Y. Blay, E. Brain, J. Alexandre, C. Kahatt, A. Taamma, J. Jimeno, C. Martin, Y. Salhi, et al.
Phase II Study of Ecteinascidin-743 in Advanced Pretreated Soft Tissue Sarcoma Patients
J. Clin. Oncol., March 1, 2004; 22(5): 890 - 899.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Morioka, L. Weissbach, T. Vogel, G. P. Nielsen, G. T. Faircloth, L. Shao, and F. J. Hornicek
Antiangiogenesis Treatment Combined with Chemotherapy Produces Chondrosarcoma Necrosis
Clin. Cancer Res., March 1, 2003; 9(3): 1211 - 1217.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Scotlandi, S. Perdichizzi, M. C. Manara, M. Serra, S. Benini, V. Cerisano, R. Strammiello, M. Mercuri, G. Reverter-Branchat, G. Faircloth, et al.
Effectiveness of Ecteinascidin-743 against Drug-sensitive and -resistant Bone Tumor Cells
Clin. Cancer Res., December 1, 2002; 8(12): 3893 - 3903.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. Gajate, F. An, and F. Mollinedo
Differential Cytostatic and Apoptotic Effects of Ecteinascidin-743 in Cancer Cells. TRANSCRIPTION-DEPENDENT CELL CYCLE ARREST AND TRANSCRIPTION-INDEPENDENT JNK AND MITOCHONDRIAL MEDIATED APOPTOSIS
J. Biol. Chem., October 25, 2002; 277(44): 41580 - 41589.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
B. A. Chabner
Cytotoxic Agents in the Era of Molecular Targets and Genomics
Oncologist, August 1, 2002; 7(90003): 34 - 41.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Friedman, Z. Hu, E. A. Kolb, B. Gorfajn, and K. W. Scotto
Ecteinascidin-743 Inhibits Activated but not Constitutive Transcription
Cancer Res., June 1, 2002; 62(12): 3377 - 3381.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. D'Incalci, E. Erba, G. Damia, E. Galliera, L. Carrassa, S. Marchini, R. Mantovani, G. Tognon, R. Fruscio, J. Jimeno, et al.
Unique Features of the Mode of Action of ET-743
Oncologist, June 1, 2002; 7(3): 210 - 216.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.